Alexandria Real Estate Equities, Inc. (ARE)

Over the past six months, Alexandria Real Estate Equities' stock has experienced significant events, with a 52-week high of $105.14 and a low of $44.10. As of February 6, 2026, the stock price was $55.90. Alexandria Real Estate Equities released its Q3 2025 earnings on October 27, 2025, with the earnings call on October 28, 2025, reporting earnings per share of $-1.38 for the quarter, with revenue of $751.94 million, exceeding analysts' expectations. The company reported its Q4 2025 earnings on January 26, 2026, with the earnings call on January 27, 2026, reporting a significant miss on earnings per share, with EPS of $-6.35, worse than the analyst estimate of $0.28, though revenue topped estimates at $754.41 million. In December 2025, Alexandria Real Estate slashed its dividend by 45%, a move that followed a period of muted tenant demand. In December 2025, the company sold or designated for held-for-sale projects with over $1 billion of basis, set a $2.9 billion dispositions target for FY 2026, launched $800 million tender offers to repurchase long-dated senior notes, and approved a $500 million share buyback. As of January 29, 2026, seventeen research firms gave ARE a consensus "Hold" rating, with an average 12-month target of $63.93, and Goldman Sachs initiated coverage with a "Neutral" rating on February 3, 2026. Alexandria's Executive Chairman Joel Marcus described 2025 as "the fifth year of a bear market" for life sciences real estate.

Demand for Alexandria Real Estate Equities' products and services is influenced by the broader life sciences industry and government funding for research. The company has been suffering from muted tenant demand for a while, partly due to a weaker IPO market in recent years. While the overall life science real estate market has faced challenges, Alexandria has demonstrated resilience through its mega-campus model and strong tenant relationships, maintaining robust leasing activity. The company expects year-end occupancy to be between 91% and 92.5%. There is no explicit information suggesting a distinct seasonal pattern in demand for their properties; rather, demand appears to be more closely tied to the funding cycles and growth of the life science and technology sectors.

Alexandria Real Estate Equities, Inc. (ARE) is a REIT specializing in urban office buildings and laboratories, primarily leasing to tenants in the life science, agtech, and technology industries. Founded in 1994, it pioneered the life science real estate niche and is known for its collaborative "Megacampus™" ecosystems near universities. Alexandria also operates Alexandria Venture Investments, a venture capital arm investing in life science firms, and its business is dependent on the life sciences industry and government funding for research.

Alexandria Real Estate Equities, Inc. has a significant market presence in key innovation clusters across North America and Europe, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, Research Triangle, Texas, and Canada. Notable properties include the Alexandria Center for Life Science in Manhattan and the Alexandria Center at Kendall Square and Technology Square in the Boston area.

Alexandria Real Estate Equities has maintained a strong brand reputation over the past year. In September 2025, Newsweek named Alexandria one of the World's Most Trustworthy Companies for the second consecutive year. This followed its third consecutive inclusion as one of America's Most Trustworthy Companies earlier in 2025, reinforcing its reputation for consistency and earning the trust of customers, investors, and employees.

Alexandria Real Estate Equities' ownership is largely dominated by institutional investors. As of December 2025, 193 institutional investors held a position in ARE. The Vanguard Group Inc. is the primary institutional investor, holding 15.16% of the stock with 25.82 million shares as of December 31, 2025. Other major institutional holders include BlackRock, Inc. and State Street. Norges Bank (The Central Bank of Norway) also holds a significant stake of 9.54%. Institutional ownership percentage fell to 21.3% in December 2025 from 87.8% in September 2025.